Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension

European Respiratory Journal

Volumn 32, Issue 6, 2008, Pages 1504-1512

  Papakonstantinou, E ^a   Kouri, F M ^b   Karakiulakis, G ^a   Klagas, I ^a   Eickelberg, O ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Hyaluronic acid; Pulmonary arterial hypertension; Pulmonary arterial smooth muscle cells; Transforming growth factor 1; Vascular remodelling

Indexed keywords

BOSENTAN; GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; PROSTACYCLIN; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA1; UNIPROST;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME METABOLISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NUCLEOTIDE SEQUENCE; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ADULT; CELL DIFFERENTIATION; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOSAMINOGLYCANS; HUMANS; HYALURONIC ACID; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 58849128218     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00159507     Document Type: Article

References (37)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-725.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
3. Eickelberg O, Morty RE. Transforming growth factor-β/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited. Trends Cardiovasc Med 2007; 17: 263-269.
4. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S.
5. Olschewski H, Rose F, Grünig E, et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 2001; 138: 367-377.
6. Hassoun PM. Deciphering the "matrix" in pulmonary vascular remodelling. Eur Respir J 2005; 25: 778-779.
7. Rabinovitch M. Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 2001; 22: 433-449.
8. Noble PW, Jiang D. Matrix regulation of lung injury, inflammation, and repair: the role of innate immunity. Proc Am Thorac Soc 2006; 3: 401-404.
9. Laurent GJ, Chambers RC, Hill MR, McAnulty RJ. Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis. Biochem Soc Trans 2007; 35: 647-651.
10. McAnulty RJ, Laurent GJ. Collagen synthesis and degradation in vivo. Evidence for rapid rates of collagen turnover with extensive degradation of newly synthesized collagen in tissues of the adult rat. Coll Relat Res 1987; 7: 93-104.
11. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003; 200: 423-428.
12. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007; 23: 435-461.
13. Souza-Fernandes AB, Pelosi P, Rocco PR. Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease. Crit Care 2006; 10: 237.
14. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-1179.
15. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 2001; 38: 715-728.
16. Papakonstantinou E, Karakiulakis G, Tamm M, Perruchoud AP, Roth M. Hypoxia modifies the effect of PDGF on glycosaminoglycan synthesis by primary human lung cells. Am J Physiol Lung Cell Mol Physiol 2000; 279: L825-L834.
17. Hance AJ, Crystal RG. The connective tissue of lung. Am Rev Respir Dis 1975; 112: 657-711.
18. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274: 25085-25092.
19. Csóka AB, Frost GI, Wong T, Stern R. Purification and microsequencing of hyaluronidase isozymes from human urine. FEBS Lett 1997; 417: 307-310.
20. Papakonstantinou E, Roth M, Block LH, Mirtsou-Fidani V, Argiriadis P, Karakiulakis G. The differential distribution of hyaluronic acid in the layers of human atheromatic aortas is associated with vascular smooth muscle cell proliferation and migration. Atherosclerosis 1998; 138: 79-89.
21. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000; 12: 581-586.
22. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-539.
23. Turino GM, Cantor JO. Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med 2003; 167: 1169-1175.
24. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277: 4589-4592.
25. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem 2002; 277: 4585-4588.
26. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-158.
27. Cuff CA, Kothapalli D, Azonobi I, et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001; 108: 1031-1040.
28. Chai S, Chai Q, Danielsen CC, et al. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ Res 2005; 96: 583-591.
29. Gouëffic Y, Guilluy C, Guérin P, Patra P, Pacaud P, Loirand G. Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res 2006; 72: 339-348.
30. Zakrzewicz A, Hecker M, Marsh LM, et al. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. Circulation 2007; 115: 2957-2968.
31. Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962; 4: 330-334.
32. Papakonstantinou E, Karakiulakis G, Roth M, Block LH. Platelet-derived growth factor stimulates the secretion of hyaluronic acid by proliferating human vascular smooth muscle cells. Proc Natl Acad Sci USA 1995; 92: 9881-9885.
33. Ohkawara Y, Tamura G, Iwasaki T, Tanaka A, Kikuchi T, Shirato K. Activation and transforming growth factor-β production in eosinophils by hyaluronan. Am J Respir Cell Mol Biol 2000; 23: 444-451.
34. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996; 98: 2403-2413.
35. Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277: 4581-4584.
36. Stuhlmeier KM, Pollaschek C. Differential effect of transforming growth factor-β (TGF-β) on the genes encoding hyaluronan synthases and utilization of the p38 MAPK pathway in TGF-β-induced hyaluronan synthase 1 activation. J Biol Chem 2004; 279: 8753-8760.
37. Papakonstantinou E, Roth M, Tamm M, Eickelberg O, Perruchoud AP, Karakiulakis G. Hypoxia differentially enhances the effects of transforming growth factor-beta isoforms on the synthesis and secretion of glycosaminoglycans by human lung fibroblasts. J Pharmacol Exp Ther 2002; 301: 830-837.